| CAR Group Limited (CAR) ORDINARY FULLY PAID |
Communication Services |
$11,127 |
Appendix 4G and Corporate Governance Statement
|
11 Aug 2025 8:24AM |
$37.000 |
$29.370 |
fallen by
20.62%
|
|
| CAR Group Limited (CAR) ORDINARY FULLY PAID |
Communication Services |
$11,127 |
Dividend/Distribution - CAR
|
11 Aug 2025 8:24AM |
$37.000 |
$29.370 |
fallen by
20.62%
|
|
| CAR Group Limited (CAR) ORDINARY FULLY PAID |
Communication Services |
$11,127 |
Appendix 4E and Annual Report 2025
|
11 Aug 2025 8:24AM |
$37.000 |
$29.370 |
fallen by
20.62%
|
|
CAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Reported revenue increased by 8% to $1,183.9 million.
- Reported EBITDA grew by 9% to $620.3 million.
- Net profit after tax attributable to owners increased by 10% to $275.5 million.
- Declared a final dividend of 41.5 cents per share, total dividends of 80.0 cents per share for the year.
- Strong performance across all business segments and geographical regions.
- Emphasized commitment to sustainability and improved emissions reporting.
- Strategic acquisitions contributed to growth.
- Continued focus on technological advancements and market leadership.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Advance Metals Limited (AVM) ORDINARY FULLY PAID |
Materials |
$34 |
Application for quotation of securities - AVM
|
11 Aug 2025 8:24AM |
$0.045 |
$0.070 |
risen by
55.56%
|
|
| Advance Metals Limited (AVM) ORDINARY FULLY PAID |
Materials |
$34 |
Application for quotation of securities - AVM
|
11 Aug 2025 8:24AM |
$0.045 |
$0.070 |
risen by
55.56%
|
|
| Advance Metals Limited (AVM) ORDINARY FULLY PAID |
Materials |
$34 |
Cleansing Prospectus
|
11 Aug 2025 8:24AM |
$0.045 |
$0.070 |
risen by
55.56%
|
|
| Sprintex Limited (SIX) ORDINARY FULLY PAID |
Consumer Discretionary |
$49 |
Application for quotation of securities - SIX
|
11 Aug 2025 8:24AM |
$0.045 |
$0.067 |
risen by
48.89%
|
|
| Peak Rare Earths Limited (PEK) ORDINARY FULLY PAID |
Materials |
- |
Court approves convening of Scheme Meeting
|
11 Aug 2025 8:23AM |
$0.335 |
$0.440 |
risen by
31.34%
|
|
PEK - Price-sensitive ASX Announcement
Full Release
Key Points
- The Supreme Court of Western Australia has approved the convening of a Scheme Meeting for Peak Rare Earths Limited shareholders.
- The Scheme Meeting is scheduled for 9 August 2024.
- Under the scheme, Shenghe Resources (Hong Kong) Limited will acquire all shares in Peak Rare Earths Limited.
- The Peak Board unanimously recommends the scheme in the absence of a superior proposal.
- A Scheme Booklet containing details of the scheme will be sent to shareholders and made available online.
- The Scheme Booklet includes an independent expert’s report and details regarding the background, implications, and timeline of the transaction.
- Shareholders are encouraged to read the Scheme Booklet and vote at the Scheme Meeting.
- If approved, the transaction will result in Peak Rare Earths Limited becoming a wholly owned subsidiary of Shenghe Resources (Hong Kong) Limited.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gold Mountain Limited (GMN) ORDINARY FULLY PAID |
Materials |
$22 |
Presentation - Brazilian Critical Minerals for Clean Energy
|
11 Aug 2025 8:23AM |
$0.059 |
$0.071 |
risen by
20.34%
|
|
| Gold Mountain Limited (GMN) ORDINARY FULLY PAID |
Materials |
$22 |
Presentation - Drilling REE for the Clean Energy Transition
|
11 Aug 2025 8:23AM |
$0.059 |
$0.071 |
risen by
20.34%
|
|
| Linius Technologies Limited (LNU) ORDINARY FULLY PAID |
Information Technology |
$16 |
Linius Secures $250,000 Captivate Contract
|
11 Aug 2025 8:23AM |
$0.001 |
$0.002 |
risen by
100%
|
|
LNU - Price-sensitive ASX Announcement
Full Release
Key Points
- Linius Technologies Limited secured a $250,000 contract with Captivate.
- The contract involves the implementation of Linius’ Whizzard product for video search and assembly.
- Captivate specializes in digital workplace solutions for the legal sector.
- The agreement includes initial license fees and a 12-month minimum revenue guarantee.
- This is the first six-figure Whizzard contract for Linius.
- The contract is expected to deliver scalable recurring revenues.
- Linius will support Captivate in delivering enhanced video management solutions to legal clients.
- The partnership is anticipated to drive product adoption and financial growth for Linius.
- The collaboration expands Linius’ presence and influence in the legal vertical.
- Linius considers this contract a strategic milestone toward broader commercialization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| DY6 Metals Ltd (DY6) ORDINARY FULLY PAID |
Materials |
- |
XRF analysis confirms high-quality of natural rutile
|
11 Aug 2025 8:23AM |
$0.310 |
$0.130 |
fallen by
58.06%
|
|
DY6 - Price-sensitive ASX Announcement
Full Release
Key Points
- DY6 Metals Ltd (DY6) announced that XRF analysis confirms the high-quality of natural rutile from its Machinga Project in Malawi.
- XRF (X-ray fluorescence) analysis on rutile samples demonstrates high titanium dioxide (TiO2) content and low impurity levels.
- The natural rutile is characterized by a TiO2 content of up to 97.8%, which is considered high quality for commercial purposes.
- Impurities such as iron oxide (Fe2O3), chromium oxide (Cr2O3), and vanadium oxide (V2O5) are reported to be low, supporting the premium quality of the rutile.
- The Company highlights the potential for the Machinga Project to become a significant supplier of high-quality natural rutile.
- Natural rutile is a critical mineral used in the production of titanium metal, welding electrodes, and as a feedstock for pigments.
- DY6 Metals Ltd plans further exploration and test work to define the extent and commercial viability of the rutile mineralization.
- The announcement reinforces DY6's commitment to advancing the Machinga Project and contributing to global supply chains of critical minerals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Variscan Mines Limited (VAR) ORDINARY FULLY PAID |
Materials |
- |
August Investor Webinar
|
11 Aug 2025 8:22AM |
$0.006 |
$0.004 |
fallen by
33.33%
|
|
| Cash Converters International (CCV) ORDINARY FULLY PAID |
Financials |
$231 |
CCV Australian Store Acquisitions
|
11 Aug 2025 8:22AM |
$0.330 |
$0.325 |
fallen by
1.52%
|
|
CCV - Price-sensitive ASX Announcement
Full Release
Key Points
- CCV has agreed to acquire up to 19 franchised stores in Australia to strengthen its corporate network.
- The acquisitions follow the recent successful purchase of 9 stores in South Australia.
- Transaction completion is dependent on due diligence, regulatory approvals, and agreement with franchisees.
- The acquisitions are expected to increase group revenue, EBITDA, and create operational efficiencies.
- CCV's strategy focuses on building a leading, integrated Australian retail network.
- The company reports positive trading updates, including revenue and profit growth across its segments.
- CCV emphasizes disciplined capital management and delivering shareholder returns.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Astral Resources NL (AAR) ORDINARY FULLY PAID |
Materials |
$279 |
High-Grade Gold Identified Within Kamperman Pit Shell
|
11 Aug 2025 8:22AM |
$0.170 |
$0.155 |
fallen by
8.82%
|
|
AAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Astral Resources NL has identified high-grade gold mineralisation within the Kamperman Pit Shell at the Mandilla Gold Project.
- The Mandilla Gold Project is located near Kalgoorlie in Western Australia.
- Recent drilling has intersected thick, high-grade gold zones near the surface at the Kamperman prospect.
- Significant gold assay results have been reported, supporting the potential for open pit mining.
- The results increase confidence in the resource growth potential and viability of the Kamperman area.
- Ongoing exploration activities continue to test extensions and new targets within the project.
- Further drilling and technical studies are planned to advance the resource base and project development.
- The Kamperman prospect is seen as a key component of Astral's regional development strategy.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IRIS Metals Limited (IR1) ORDINARY FULLY PAID |
Materials |
$14 |
Ceasing to be a substantial holder - NASDAQ
|
11 Aug 2025 8:22AM |
$0.086 |
$0.049 |
fallen by
43.02%
|
|
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,753 |
Notification of cessation of securities - NWS
|
11 Aug 2025 8:22AM |
$51.450 |
$46.600 |
fallen by
9.43%
|
|
| News Corporation (NWS) CLASS B VOTING COMMON STOCK-CDI 1:1 |
Communication Services |
$1,753 |
Notification of cessation of securities - NWS
|
11 Aug 2025 8:22AM |
$51.450 |
$46.600 |
fallen by
9.43%
|
|
| Invex Therapeutics Ltd (IXC) ORDINARY FULLY PAID |
Health Care |
$9 |
Appendix 4E and Annual Report to shareholders
|
11 Aug 2025 8:22AM |
$0.090 |
$0.115 |
risen by
27.78%
|
|
IXC - Price-sensitive ASX Announcement
Full Release
Key Points
- Invex Therapeutics Ltd is focused on developing Presendin for conditions involving raised intracranial pressure, including IIH.
- During FY2023, Invex made significant progress in its Phase III IIH EVOLVE clinical trial, with approvals and site initiations in Europe, the UK, and Australia.
- The company reported a net loss of $6,978,822 for the financial year ending 30 June 2023.
- Invex had a cash balance of $22,490,728, providing a strong runway for ongoing operations.
- No dividends were paid or proposed for the period.
- Key risks identified include regulatory, clinical, intellectual property, supply chain, and commercialisation risks.
- The company maintains a focused drug development strategy, leveraging its intellectual property portfolio and experienced management team.
- Invex expects continued advancement in clinical trials and regulatory interactions through the coming year.
- The board and management remain committed to transparent reporting and prudent financial management.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Block, Inc. (XYZ) CDI 1:1 FOREIGN EXEMPT NYSE |
Financials |
$4,273 |
Notice of Proposed Sale of Securities
|
11 Aug 2025 8:22AM |
$127.090 |
$112.600 |
fallen by
11.40%
|
|
| ResMed Inc. (RMD) CDI 10:1 FOREIGN EXEMPT NYSE |
Health Care |
$18,468 |
Resmed Form 10-K Annual Report
|
11 Aug 2025 8:21AM |
$43.020 |
$31.230 |
fallen by
27.41%
|
|
RMD - Price-sensitive ASX Announcement
Full Release
Key Points
- Net revenue increased by 10% to $5.146 billion.
- Net income rose to $1.401 billion in 2025.
- Cash provided by operating activities increased to $1.751 billion.
- Significant growth in Sleep and Breathing Health and Residential Care Software segments.
- Earnings per share increased to $9.55 (basic) and $9.51 (diluted).
- Dividends paid were $2.12 per share.
- Investment in property, plant, and equipment decreased.
- Treasury stock repurchases of $300 million.
- Global leader in respiratory disorder management solutions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ResMed Inc. (RMD) CDI 10:1 FOREIGN EXEMPT NYSE |
Health Care |
$18,468 |
Resmed Form 10-K Annual Report
|
11 Aug 2025 8:21AM |
$43.020 |
$31.230 |
fallen by
27.41%
|
|
RMD - Price-sensitive ASX Announcement
Full Release
Key Points
- ResMed's net income for the year ended June 30, 2025, was $1,400,723,000.
- Basic earnings per share for 2025 were $9.55.
- The Sleep and Breathing Health segment was a major contributor to revenue.
- KPMG LLP audited the financial statements.
- ResMed is a leader in devices for diagnosing and managing respiratory disorders.
- The annual report includes management's discussion of financial condition and results of operations.
- The report was signed by CEO Michael J. Farrell and CFO Brett A. Sandercock.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Capstone Copper Corp. (CSC) CDI 1:1 FOREIGN EXEMPT TSX |
Materials |
$3,389 |
Capstone Copper Announces Sanctioning of MVO Project
|
11 Aug 2025 8:21AM |
$9.660 |
$15.890 |
risen by
64.49%
|
|
| Mineral Resources Limited (MIN) ORDINARY FULLY PAID |
Materials |
$12,949 |
Becoming a substantial holder
|
11 Aug 2025 8:21AM |
$33.980 |
$65.220 |
risen by
91.94%
|
|
| NEXTDC Limited (NXT) ORDINARY FULLY PAID |
Information Technology |
$10,983 |
Becoming a substantial holder
|
11 Aug 2025 8:21AM |
$14.510 |
$14.460 |
fallen by
0.34%
|
|
Call 1300 880 160
Start a chat
Schedule a call
